Home / Healthcare / Neuroblastoma - Pipeline Review, H1 2015

Neuroblastoma - Pipeline Review, H1 2015

Published: Jun 2015 | No Of Pages: 308 | Published By: Global Markets Direct

Neuroblastoma - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Neuroblastoma - Pipeline Review, H1 2015', provides an overview of the Neuroblastoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neuroblastoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neuroblastoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Neuroblastoma Overview 10
Therapeutics Development 11
Pipeline Products for Neuroblastoma - Overview 11
Pipeline Products for Neuroblastoma - Comparative Analysis 12
Neuroblastoma - Therapeutics under Development by Companies 13
Neuroblastoma - Therapeutics under Investigation by Universities/Institutes 18
Neuroblastoma - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Neuroblastoma - Products under Development by Companies 23
Neuroblastoma - Products under Investigation by Universities/Institutes 28
Neuroblastoma - Companies Involved in Therapeutics Development 30
Ability Pharma, SL 30
Acetylon Pharmaceuticals, Inc. 31
Advanced Accelerator Applications SA 32
Aeterna Zentaris Inc. 33
Ampio Pharmaceuticals, Inc. 34
APEIRON Biologics AG 35
Aptose Biosciences Inc. 36
AstraZeneca Plc 37
Bellicum Pharmaceuticals, Inc. 38
Bexion Pharmaceuticals, LLC. 39
BioLineRx, Ltd. 40
Bionucleon Srl 41
Cebiotex, S.L. 42
Celgene Corporation 43
Chugai Pharmaceutical Co., Ltd. 44
Cleveland BioLabs, Inc. 45
CureFAKtor Pharmaceuticals, LLC 46
DEKK-TEC, Inc. 47
Errant Gene Therapeutics, LLC 48
F. Hoffmann-La Roche Ltd. 49
Gamida Cell Ltd. 50
Ignyta, Inc. 51
Juno Therapeutics Inc. 52
Lindis Biotech GmbH 53
MabVax Therapeutics Holdings, Inc. 54
Merck & Co., Inc. 55
Merrimack Pharmaceuticals, Inc. 56
Netris Pharma S.A.S. 57
Novartis AG 58
Novogen Limited 59
Pono Pharma 60
Progenics Pharmaceuticals, Inc. 61
Recombio S.L 62
Sareum Holdings Plc 63
Shionogi & Co., Ltd. 64
Sutro Biopharma, Inc. 65
Teva Pharmaceutical Industries Limited 66
Threshold Pharmaceuticals, Inc. 67
United Therapeutics Corporation 68
Neuroblastoma - Therapeutics Assessment 69
Assessment by Monotherapy Products 69
Assessment by Combination Products 70
Assessment by Target 71
Assessment by Mechanism of Action 76
Assessment by Route of Administration 80
Assessment by Molecule Type 82
Drug Profiles 84
1-B7 - Drug Profile 84
31-F9 - Drug Profile 85
ABTL-0812 - Drug Profile 86
ACY-957 - Drug Profile 88
AMXT-1501 + eflornithine hydrochloride - Drug Profile 89
APN-301 - Drug Profile 91
APN-311 - Drug Profile 93
ATM-3507 - Drug Profile 95
AZ-64 - Drug Profile 96
BACPT-DP - Drug Profile 97
bevacizumab - Drug Profile 99
BL-8040 - Drug Profile 104
BN-210 - Drug Profile 106
BPX-701 - Drug Profile 107
BXQ-350 - Drug Profile 108
CCT-137690 - Drug Profile 110
CCT-244747 - Drug Profile 111
CEB-01 - Drug Profile 113
Cell Therapy for GD2 Expressing Solid Tumors - Drug Profile 114
Cell Therapy for Neuroblastoma - Drug Profile 115
Cell Therapy to Target GD2 for Neuroblastoma - Drug Profile 116
Cell Therapy to Target GD2 for Neuroblastoma - Drug Profile 117
celyvir - Drug Profile 118
CEP-28122 - Drug Profile 120
CFAKC-4 - Drug Profile 121
CFAKY-15 - Drug Profile 122
CG-1521 - Drug Profile 123
cVE-199 - Drug Profile 124
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 125
dinutuximab - Drug Profile 126
Drugs to Activate Caspase 3 for Oncology - Drug Profile 128
Edotreotide Labeled Yttrium 90 - Drug Profile 129
eflornithine hydrochloride - Drug Profile 131
eh8B6 - Drug Profile 133
entrectinib - Drug Profile 134
evofosfamide - Drug Profile 136
firtecan pegol - Drug Profile 144
FSEC - Drug Profile 146
iobenguane sulfate I 131 - Drug Profile 147
irinotecan sucrosofate liposomal - Drug Profile 149
JCAR-023 - Drug Profile 152
Lutathera - Drug Profile 153
M-606 - Drug Profile 155
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 156
Monoclonal Antibody to Target CD3 for Neuroblastoma - Drug Profile 157
Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastom - Drug Profile 158
Monoclonal Antibody to Target GD2 and CD3 for Neuroblastoma - Drug Profile 160
Monoclonal Antibody to Target GD2 for Neuroblastoma - Drug Profile 161
NCE-001 - Drug Profile 162
NTX-010 - Drug Profile 163
Oncolytic Virus for Oncology - Drug Profile 165
P-937 - Drug Profile 166
paclitaxel albumin bound - Drug Profile 167
pazopanib hydrochloride - Drug Profile 170
pembrolizumab - Drug Profile 175
Peptide to Inhibit HDAC for Neuroblastoma - Drug Profile 182
perifosine - Drug Profile 183
racotumomab - Drug Profile 186
Recombinant Protein to Inhibit HDAC for Neuroblastoma - Drug Profile 188
ribociclib - Drug Profile 189
RKS-262 - Drug Profile 192
RNAi Oligonucleotide for Oncology - Drug Profile 193
RNAi Oligonucleotides for Neuroblastoma - Drug Profile 194
RSF-701 - Drug Profile 195
S-588410 - Drug Profile 196
SAR-020106 - Drug Profile 197
SF-1126 - Drug Profile 199
Small Molecule to Target Netrin-1 Ligand for Oncology - Drug Profile 201
Small Molecules for Neuroblastoma - Drug Profile 202
Small Molecules for Neuroblastoma - Drug Profile 203
Small Molecules to Antagonize ALK for Oncology - Drug Profile 204
Small Molecules to Inhibit Aurora and ALK Kinase for Oncology - Drug Profile 205
Small Molecules to Inhibit Aurora Kinase and FLT3 Kinase for Oncology - Drug Profile 206
SRX-2523 - Drug Profile 208
Stem Cells to Activate Natural Killer Cell for Adoptive Cell-Mediated Therapy - Drug Profile 210
Syrbactins - Drug Profile 211
TL-118 - Drug Profile 212
TPI-287 - Drug Profile 214
TR-100 - Drug Profile 216
TRBS-07 - Drug Profile 217
Trilexium - Drug Profile 218
Vaccine for Neuroblastoma - Drug Profile 219
Vaccine for Neuroblastoma - Drug Profile 221
Vaccine for Neuroblastoma - Drug Profile 222
Vaccine for Neuroblastoma - Drug Profile 223
Neuroblastoma - Recent Pipeline Updates 224
Neuroblastoma - Dormant Projects 287
Neuroblastoma - Discontinued Products 290
Neuroblastoma - Product Development Milestones 291
Featured News & Press Releases 291
Appendix 301
Methodology 301
Coverage 301
Secondary Research 301
Primary Research 301
Expert Panel Validation 301
Contact Us 301
Disclaimer 302

Number of Products under Development for Neuroblastoma, H1 2015 17
Number of Products under Development for Neuroblastoma - Comparative Analysis, H1 2015 18
Number of Products under Development by Companies, H1 2015 20
Number of Products under Development by Companies, H1 2015 (Contd..1) 21
Number of Products under Development by Companies, H1 2015 (Contd..2) 22
Number of Products under Development by Companies, H1 2015 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2015 25
Comparative Analysis by Late Stage Development, H1 2015 26
Comparative Analysis by Clinical Stage Development, H1 2015 27
Comparative Analysis by Early Stage Development, H1 2015 28
Products under Development by Companies, H1 2015 29
Products under Development by Companies, H1 2015 (Contd..1) 30
Products under Development by Companies, H1 2015 (Contd..2) 31
Products under Development by Companies, H1 2015 (Contd..3) 32
Products under Development by Companies, H1 2015 (Contd..4) 33
Products under Investigation by Universities/Institutes, H1 2015 34
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 35
Neuroblastoma - Pipeline by Ability Pharma, SL, H1 2015 36
Neuroblastoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 37
Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H1 2015 38
Neuroblastoma - Pipeline by Aeterna Zentaris Inc., H1 2015 39
Neuroblastoma - Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 40
Neuroblastoma - Pipeline by APEIRON Biologics AG, H1 2015 41
Neuroblastoma - Pipeline by Aptose Biosciences Inc., H1 2015 42
Neuroblastoma - Pipeline by AstraZeneca Plc, H1 2015 43
Neuroblastoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 44
Neuroblastoma - Pipeline by Bexion Pharmaceuticals, LLC., H1 2015 45
Neuroblastoma - Pipeline by BioLineRx, Ltd., H1 2015 46
Neuroblastoma - Pipeline by Bionucleon Srl, H1 2015 47
Neuroblastoma - Pipeline by Cebiotex, S.L., H1 2015 48
Neuroblastoma - Pipeline by Celgene Corporation, H1 2015 49
Neuroblastoma - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 50
Neuroblastoma - Pipeline by Cleveland BioLabs, Inc., H1 2015 51
Neuroblastoma - Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015 52
Neuroblastoma - Pipeline by DEKK-TEC, Inc., H1 2015 53
Neuroblastoma - Pipeline by Errant Gene Therapeutics, LLC, H1 2015 54
Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 55
Neuroblastoma - Pipeline by Gamida Cell Ltd., H1 2015 56
Neuroblastoma - Pipeline by Ignyta, Inc., H1 2015 57
Neuroblastoma - Pipeline by Juno Therapeutics Inc., H1 2015 58
Neuroblastoma - Pipeline by Lindis Biotech GmbH, H1 2015 59
Neuroblastoma - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015 60
Neuroblastoma - Pipeline by Merck & Co., Inc., H1 2015 61
Neuroblastoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 62
Neuroblastoma - Pipeline by Netris Pharma S.A.S., H1 2015 63
Neuroblastoma - Pipeline by Novartis AG, H1 2015 64
Neuroblastoma - Pipeline by Novogen Limited, H1 2015 65
Neuroblastoma - Pipeline by Pono Pharma, H1 2015 66
Neuroblastoma - Pipeline by Progenics Pharmaceuticals, Inc., H1 2015 67
Neuroblastoma - Pipeline by Recombio S.L, H1 2015 68
Neuroblastoma - Pipeline by Sareum Holdings Plc, H1 2015 69
Neuroblastoma - Pipeline by Shionogi & Co., Ltd., H1 2015 70
Neuroblastoma - Pipeline by Sutro Biopharma, Inc., H1 2015 71
Neuroblastoma - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 72
Neuroblastoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 73
Neuroblastoma - Pipeline by United Therapeutics Corporation, H1 2015 74
Assessment by Monotherapy Products, H1 2015 75
Assessment by Combination Products, H1 2015 76
Number of Products by Stage and Target, H1 2015 78
Number of Products by Stage and Mechanism of Action, H1 2015 83
Number of Products by Stage and Route of Administration, H1 2015 87
Number of Products by Stage and Molecule Type, H1 2015 89
Neuroblastoma Therapeutics - Recent Pipeline Updates, H1 2015 230
Neuroblastoma - Dormant Projects, H1 2015 293
Neuroblastoma - Dormant Projects (Contd..1), H1 2015 294
Neuroblastoma - Dormant Projects (Contd..2), H1 2015 295
Neuroblastoma - Discontinued Products, H1 2015 296

Number of Products under Development for Neuroblastoma, H1 2015 17
Number of Products under Development for Neuroblastoma - Comparative Analysis, H1 2015 18
Number of Products under Development by Companies, H1 2015 19
Number of Products under Investigation by Universities/Institutes, H1 2015 24
Comparative Analysis by Late Stage Development, H1 2015 26
Comparative Analysis by Clinical Stage Development, H1 2015 27
Comparative Analysis by Early Stage Products, H1 2015 28
Assessment by Monotherapy Products, H1 2015 75
Number of Products by Top 10 Targets, H1 2015 77
Number of Products by Stage and Top 10 Targets, H1 2015 77
Number of Products by Top 10 Mechanism of Actions, H1 2015 82
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 82
Number of Products by Top 10 Routes of Administration, H1 2015 86
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 86
Number of Products by Top 10 Molecule Types, H1 2015 88
Number of Products by Stage and Top 10 Molecule Types, H1 2015 88

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +